Skip to main content
. Author manuscript; available in PMC: 2017 Aug 17.
Published in final edited form as: Mol Cancer Ther. 2015 Jun 10;14(8):1962–1971. doi: 10.1158/1535-7163.MCT-15-0153

Table 4.

Molecular Events and Related Tumor Board Recommendations in Five Patients

Patient ID Number of Somatic
Coding Mutations		 Key Somatic Events Therapeutic
Relationship
Patient 001 3,126 BRAF(D594G), CDKN2A(Deletion), MAP2K1(E203K) MEK162
Patient 002 3,364 NF1(R440X), RB1(S646F) MEK162
Patient 003 183 NRAS(Q61R), CDKN2A(Deletion) MEK162
Patient 004 44 PTEN(HmzDel), CSF1R(Over expression), FLT1(OExp), PDGFRB(Over Expression) PLX3397
Patient 005 369 NRAS(Q61R), PTEN(Loss of function frameshift), CDKN2A(Deletion), TP53(Deletion) MEK162

BRAF, v-Raf murine sarcoma viral oncogene homolog B; CDKN2A, cyclin-dependent kinase inhibitor 2A; MAP2K1, mitogen-activated protein kinase kinase 1; NF1, neurofibromin 1; RB1, retinoblastoma 1; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; PTEN, phosphatase and tensin homolog, CSF1R, colony stimulating factor 1 receptor; FLT1, fms-related tyrosine kinase 1; PDGFRB, platelet-derived growth factor receptor, beta polypeptide; TP53, tumor protein p53